Abstract
This Patent Highlight delves into the potential of next-generation therapeutics for treating mental disorders and modulating the central nervous system (CNS). Among the serotonin receptor subtypes, 5-HT2A, 5-HT2C, 5-HT1A, and 5-HT1B have shown promise in CNS disorder treatment. Approved drugs targeting these receptors, such as antipsychotics and psychedelics, provide valuable insights into their therapeutic effects. However, modulation of these receptors can lead to side effects like hallucinations and altered perception. The development of 5-HT2A agonists with minimized mood changes and improved therapeutic benefits is crucial. Furthermore, exploring morphic salt mixtures and specified salts offers innovative approaches to effectively modulating CNS activity and treating mental disorders.